NASDAQ · Biotechnology

LXRX (LXRX) Stock

$2.47 +4.66% NASDAQ: LXRX Healthcare

Valuation

MetricValue
Price$2.47
Market Cap$1.10B
P/E Ratio-15.93
P/B Ratio9.17
P/S Ratio13.65
EPS (TTM)$-0.14
52-Week High$2.66
52-Week Low$0.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-46.30%
ROA-27.03%
ROCE-45.37%
Gross Margin-98.00%
Operating Margin-98.00%
Net Margin-37.46%
Debt/Equity0.28
Current Ratio4.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$31.0M$50.0M
Operating Profit$-87.0M$-101.0M$-172.0M$-197.0M$-49.0M
Net Profit$-88.0M$-102.0M$-177.0M$-200.0M$-50.0M
EPS$-0.61$-0.62$-0.80$-0.63$-0.14
Op Margin-29224.8%-72489.2%-14265.0%-634.2%-98.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$137.0M$194.0M$229.0M$298.0M$185.0M
Total Liabilities$23.0M$77.0M$136.0M$152.0M$77.0M
Cash$64.0M$46.0M$22.0M$67.0M$34.0M
Borrowings$2.0M$55.0M$106.0M$108.0M$62.0M

Latest News

Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion Insider Monkey · Jul 3, 2026 Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? Insider Monkey · Jun 11, 2026 Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? Motley Fool · Jun 11, 2026 How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates Simply Wall St. · Jun 4, 2026 Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions GlobeNewswire · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-87.0M$-89.0M$-162.0M$-179.0M$-68.0M
Investing Cash Flow$1.0M$-72.0M$-50.0M$-16.0M$113.0M
Financing Cash Flow$-3.0M$93.0M$-1.0M$-3.0M$-1.0M
Net Cash Flow$-62.0M$-18.0M$-24.0M$44.0M$-3.0M
Free Cash Flow$-88.0M$-90.0M$-162.0M$-180.0M$-68.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-4.08%
Quick Ratio18.77
Interest Coverage-6.12
Return 1Y90.08%
Return 3Y15.00%
Return 5Y-42.55%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADCTADC Therapeutics S.A. $1.19 +3.48% -1.09 $151.36M 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CMPX $1.89 -4.55% -4.71 $340.37M 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
FULC $3.73 +0.13% -5.17 $201.56M 0.00%

About LXRX

LXRX is led by CEO Michael S. Exton, employs 103 people, headquartered in US, publicly traded since 2000.

LXRX stock trades at $2.47 with a market capitalization of $1.10B. The stock is valued at a price-to-earnings (P/E) ratio of -15.93, price-to-book of 9.17, price-to-sales of 13.65. Over the past 52 weeks the stock has ranged between $0.72 and $2.66, and currently trades 7.1% below its 52-week high.

On profitability, LXRX generates a return on equity (ROE) of -46.30%, return on capital employed of -45.37%, an operating margin of -98.00%, a net profit margin of -37.46%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides